Valuation of Your Early Drug Candidate
Best Practices for Fundraising and M&A Due Diligence
This whitepaper explores the importance of establishing early goals and objectives for the process, how to get the right people to ask the right questions in advance of the process, how to build credibility by defining goals and demonstrating they can be achieved, and much more.
Getting Ready for a Biopharma Partnering Deal
The Nuts & Bolts of Due Diligence in Biopharma Partnering
What's Hot and What's Not in Oncology Licensing in 2020?
How to Win at the Partnering Game
In this white paper, Linda Pullan provides a review of the rules of the partnering game – whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy.
What’s Hot & What’s Not in Immuno-Oncology Licensing
Non-Immuno-Oncology and Immuno-Oncology Partnering and Development: What’s the Role of Non-IO in an IO World?
What’s Hot & What’s Not in Oncology Licensing in 2020?
Building a Better Partnering Presentation
Whether seeking a partnership with another company to obtain funds, or looking to advance a drug candidate or technology, organizations need to present opportunities as attractively as possible to persuade potential partners.